Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03084861
Recruitment Status : Terminated (Low recruitment. No safety issue associated.)
First Posted : March 21, 2017
Last Update Posted : October 27, 2020
Sponsor:
Information provided by (Responsible Party):
Banc de Sang i Teixits

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multicenter, randomized, open-label, two-arms phase I/II, clinical trial, in which 42 patients will be enrolled with the principal objective to evaluate the efficacy through changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal sensibility, corneal opacity, visual acuity and complications of Neurotrophic Keratopathy (NK). Patients will be randomized 1:1 to receive experimental treatment (cord blood eye drops) or conventional treatment (artificial tears and therapeutic contact lens).

Condition or disease Intervention/treatment Phase
Neurotrophic Keratopathy Drug: Cord Blood Eye Drops Drug: Conventional treatment Phase 1 Phase 2

Detailed Description:

This is a multicenter, randomized, open-label, two-arms phase I/II, clinical trial, in which 42 patients will be enrolled with the principal objective to evaluate the efficacy through changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal sensibility, corneal opacity, visual acuity and complications of NK. Patients will be randomized 1:1 to receive experimental treatment (cord blood eye drops) or conventional treatment (artificial tears and therapeutic contact lens).

All patients, with conventional or experimental treatment, will be treated for 19 days. A topical antibiotic will be added too as a concomitant treatment to all treatment groups, until the injury closes or according to medical criteria.

After signing informed consent, inclusion and exclusion criteria will be assessed, and if the patient meets all the requirements, the patient will be randomized.

After initiation of the treatment, patients will be follow-up at 2-3 days and once a week for 3 weeks. A final follow-up is planned at 6 weeks.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: open label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Open-label, Two-arms Phase I/II Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
Actual Study Start Date : February 24, 2017
Actual Primary Completion Date : March 12, 2020
Actual Study Completion Date : March 12, 2020
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: cord blood eye drops
Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
 Drug: Cord Blood Eye Drops
Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
Active Comparator: Conventional treatment

Conventional treatment:

  1. Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic
  2. Therapeutic Contact lens Description: Air Optix Night&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular
 Drug: Conventional treatment
  1. Artificial tears: Lubristil ®
  2. Therapeutic Contact lens: Air Optix Night&Day


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Corneal lesion size [ Time Frame: after 3 weeks post-treatment, ]
    Variation percentage in corneal lesion size


Secondary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: From date of randomization until the date of the last visit (6 weeks post-treatment) ]
    Safety evaluation through laboratory data and adverse events

  2. Corneal lesion size [ Time Frame: at 2-3 days post-treatment and at 1, 2 and 6 weeks post-treatment ]
    Variation percentage in corneal lesion size

  3. Stage on the corneal lesion [ Time Frame: at 3 weeks post-treatment ]
    Changes stage on the corneal lesion (cured, stage 1, stage 2, stage 3) from baseline

  4. Qualitative scale of corneal sensibility [ Time Frame: at 2-3 days post-treatment and at 1, 2, 3 and 6 weeks post-treatment ]
    Changes in qualitative scale of corneal sensibility (normoesthesia, hypoesthesia, anesthesia)

  5. Corneal opacity [ Time Frame: at 2-3 days post-treatment and at 1, 2, 3 and 6 weeks post-treatment ]
    Changes on corneal opacity from baseline (not response, improvement, worse)

  6. Visual acuity [ Time Frame: at 2-3 days post-treatment and at 1, 2 and 6 weeks post-treatment ]
    Line variation in relation to visual acuity

  7. Neurotrophic keratopathy [ Time Frame: From date of randomization until the date of the last visit (6 weeks post-treatment) ]
    Number of neurotrophic keratopathy complications


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. NK stage 2 or 3 (Mackie classification)
  3. Signed Informed Consent Form
  4. The patient is able to understand the nature of the study and to participate throughout its duration

Exclusion Criteria:

  1. Medical history of eye tumors
  2. Active eye infection
  3. Eyelid bad position or eyelid closure problems
  4. Conjunctiva scarring
  5. Topic chronic eye treatments with corticoids
  6. Acute corneal burns (<3 months)
  7. Intolerance to contact lens
  8. Allergy or inability to receive concomitant treatment with Exocin®
  9. Patients with immunosuppressive or chemotherapy treatment
  10. Pregnant woman or woman without proper contraceptive methods according to the investigator (*), or lactating women
  11. Participation in another clinical trial in the last month (*) Contraceptive methods accepted in the protocol are: hormonal, intrauterine device (IUD), barrier methods, voluntary sterilization or the patient has menopause >1 year duration
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03084861


Locations
Layout table for location information
Spain
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916
Hospital Mútua de Terrassa
Terrassa, Barcelona, Spain, 08221
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain, 08026
Hospital Vall d'Hebron
Barcelona, Catalonia, Spain, 08035
Instituto Oftalmológico Quirónsalud Barcelona
Barcelona, Spain, 08017
Hospital de l'Esperança
Barcelona, Spain, 08024
Institut de microcirurgia ocular IMO
Barcelona, Spain, 08035
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain, 08036
Hospital Josep Trueta
Girona, Spain, 17007
Hospital Joan XXIII
Tarragona, Spain, 43005
Sponsors and Collaborators
Banc de Sang i Teixits
Investigators
Layout table for investigator information
Principal Investigator: Sergi Querol Giner, MD PHD Banc de Sang i Teixits
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Banc de Sang i Teixits
ClinicalTrials.gov Identifier: NCT03084861    
Other Study ID Numbers: I.2016.010
First Posted: March 21, 2017    Key Record Dates
Last Update Posted: October 27, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ophthalmic Solutions
Pharmaceutical Solutions